Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Xiaomi Shares Jump on Europe EV Expansion Plan 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Milei Threatens Falkland Oil Firms With Sanctions 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., March 01, 2018 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced that the company’s management will participate in two upcoming investor conferences.
- Sean McCarthy, D. Phil., president and chief executive officer, will present at the Cowen and Company 38th Annual Healthcare Conference on March 13, 2018, at 10:00 a.m. ET.
- Debanjan Ray, Chief Financial Officer and Head of Corporate Development, will present at the Barclay’s Global Health Conference on March 15, 2018, at 8:30 a.m. ET.
A live audio webcast for each event will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, such as CX-072, a PD-L1-targeting Probody therapeutic and BMS-986249, a CTLA-4-targeting Probody therapeutic, and first-in-class Probody drug conjugates against highly attractive targets, such as CX-2009, a CD166-targeting Probody drug conjugate and CX-2029, a CD71-targeting Probody drug conjugate, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, Pfizer and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
CytomX Therapeutics
Media:
Spectrum
Christine Quern
[email protected]
202-587-2588
Investors:
Trout Group
Pete Rahmer
[email protected]
646-378-2973
